<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798430</url>
  </required_header>
  <id_info>
    <org_study_id>LIB003-007</org_study_id>
    <nct_id>NCT04798430</nct_id>
  </id_info>
  <brief_title>Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction</brief_title>
  <acronym>LIBerate-OLE</acronym>
  <official_title>Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With HoFH and HeFH, CVD, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIB Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LIB Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to assess the long-term safety, tolerability, and efficacy after 48 and 72 weeks&#xD;
      with monthly (Q4W [&lt;31 days]) dosing of subcutaneous (SC) LIB003 300 mg administered in&#xD;
      patients with CVD or at high risk for CVD (including HoFH and HeFH) on stable diet and oral&#xD;
      LDL-C lowering drug therapy who completed one of the LIB003 Phase 3 base studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The population for this open-label study includes patients who successfully complete one of&#xD;
      the randomized, controlled (placebo or comparator) blinded Phase 3 base studies (LIB003-003,&#xD;
      LIB003-004, LIB003-005, LIB003-006, LIB003-008, LIB003-011 and LIB003-012). Patients will&#xD;
      continue to maintain their existing oral lipid-lowering therapy (LLT).&#xD;
&#xD;
      Following completion of a base study and providing informed consent, patients will receive&#xD;
      doses of LIB003 300 mg Q4W (&lt;31 days) on Day 1 and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36,&#xD;
      40, 44, 48, 52, 56, 60, 64, and 68. Patients will be seen in the clinic Q4W (&lt;31 days) for at&#xD;
      least the initial 12 weeks and then every 12 weeks (Weeks 24, 36, 48, 60, and 72) with the&#xD;
      interim Q4W (&lt;31 days) doses administered at home.&#xD;
&#xD;
      Patients may begin the OLE on the final visit of their prior study after completion of all&#xD;
      requirements for that trial. Their lipids will remain blinded (to patient, study staff and&#xD;
      sponsor) until week 4 to avoid any unblinding of the prior trial. Thereafter lipid results&#xD;
      will be unblinded throughout the remainder of the 72 week trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open label extension trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>lipids blinded to participant, investigator and sponsor at Day 1 only</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by Medical Dictionary for Regulatory Activities as severe, moderate or mild after 48 and 72 weeks</measure>
    <time_frame>72 weeks</time_frame>
    <description>Evaluation of Adverse Events based on MedRA based on ITT population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>72 weeks</time_frame>
    <description>Incidence of anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol reduction</measure>
    <time_frame>72 weeks</time_frame>
    <description>Percent decrease in LDL-C from baseline of original study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Cardiovascular Disease With Mention of Arteriosclerosis</condition>
  <condition>Elevated Cholesterol</condition>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>LIB003 (lerodalcibep)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg monthly (Q4W) by subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lerodalcibep</intervention_name>
    <description>PCSK9 inhibitor</description>
    <arm_group_label>LIB003 (lerodalcibep)</arm_group_label>
    <other_name>LIB003</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Successful completion 1 of one of the Phase 3 base studies LIB003-003, LIB003-004,&#xD;
             LIB003-005, LIB003-006, LIB003-008, LIB003-011 and LIB003-012 without SAEs related to&#xD;
             LIB003; or&#xD;
&#xD;
          -  Provision of written and signed informed consent prior to any study-specific&#xD;
             procedure;&#xD;
&#xD;
          -  Female patients of childbearing potential must be using a highly effective form of&#xD;
             birth control if sexually active and have a negative urine pregnancy test on Day 1&#xD;
             prior to dosing;&#xD;
&#xD;
          -  Patient is willing to maintain appropriate diet and stable dose of current&#xD;
             lipid-lowering therapy including statins, ezetimibe, bile acid sequestrants, niacin,&#xD;
             bempedoic acid, bezafibrate or fenofibrate, and/or OM-3 compounds; and&#xD;
&#xD;
          -  Patient is considered by the Investigator to be otherwise healthy,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to complete a base Phase 3 (LIB003-003, LIB003-004, LIB003-005, LIB003-006,&#xD;
             LIB003-008, LIB003-011 and LIB003-012) study and/or had an SAE that was related to&#xD;
             study drug during the base Phase 3 study;&#xD;
&#xD;
          -  Development since the final visit in the base Phase 3 (LIB003-003, LIB003-004,&#xD;
             LIB003-005, LIB003-006, LIB003-008, LIB003-011 or LIB003-012) study of any concomitant&#xD;
             clinical condition or acute and/or unstable systemic disease compromising patient&#xD;
             inclusion, at the discretion of the Investigator,&#xD;
&#xD;
          -  Use of prohibited oral lipid-lowering agents PCSK9 mAbs, mipomersen, lomitapide&#xD;
             gemfibrozil (or bempedoic acid for LIB003, -011) following the base study or the use&#xD;
             of PCSK9 short interfering ribonucleic acid (siRNA), or locked nucleic acid-reducing&#xD;
             agents (LNA) within the last 6 months;&#xD;
&#xD;
          -  Not available for protocol-required study visits or procedures, to the best of the&#xD;
             patient's and Investigator's knowledge;&#xD;
&#xD;
          -  Has any other finding which, in the opinion of the Investigator, would compromise the&#xD;
             patient's safety or participation in the study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kallend, MB BCh</last_name>
    <role>Study Director</role>
    <affiliation>LIB Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic &amp; Atherosclerosis Research Center (MARC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.B. Pant Institute of Postgraduate Medical Education &amp; Research</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>12000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital,</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipid Clinic, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0586</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carbohydrate and Lipid Metabolism Research Unit</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Lipidology, Department of Medicine University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical School</name>
      <address>
        <city>İzmir</city>
        <state>Bornova</state>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afyonkarahisar Health Sciences University</name>
      <address>
        <city>Afyon</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Israel</country>
    <country>Norway</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lerodalcibep</keyword>
  <keyword>PCSK9 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

